Aripiprazole Patent Expiration
Aripiprazole is used for acute treatment of manic and mixed episodes associated with bipolar I disorder, adjunctive treatment of major depressive disorder (MDD), and treatment of schizophrenia. It was first introduced by Otsuka Pharmaceutical Co Ltd
Aripiprazole Patents
Given below is the list of patents protecting Aripiprazole, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Abilify Mycite Kit | US10097388 | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping | Sep 19, 2034 | Otsuka |
Abilify Mycite Kit | US9270503 | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping | Sep 19, 2034 | Otsuka |
Abilify Mycite Kit | US9787511 | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping | Sep 19, 2034 | Otsuka |
Abilify Maintena Kit | US11648347 | Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient | Apr 06, 2034 | Otsuka Pharm Co Ltd |
Abilify Maintena Kit | US10525057 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | Mar 08, 2034 | Otsuka Pharm Co Ltd |
Abilify Mycite Kit | US9268909 | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device | Oct 15, 2033 | Otsuka |
Abilify Mycite Kit | US9577864 | Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance | Oct 03, 2033 | Otsuka |
Abilify Maintena Kit | US10980803 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | Sep 24, 2033 | Otsuka Pharm Co Ltd |
Abilify Maintena Kit | US11154553 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | Sep 24, 2033 | Otsuka Pharm Co Ltd |
Abilify Maintena Kit | US11344547 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | Sep 24, 2033 | Otsuka Pharm Co Ltd |
Abilify Maintena Kit | US11400087 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | Sep 24, 2033 | Otsuka Pharm Co Ltd |
Abilify Asimtufii | US10517951 | Injectable preparation | Apr 23, 2033 | Otsuka |
Abilify Asimtufii | US11097007 | Injectable preparation | Apr 23, 2033 | Otsuka |
Abilify Asimtufii | US11638757 | Injectable preparation | Apr 23, 2033 | Otsuka |
Abilify Asimtufii | US12016927 | Injectable preparation | Apr 23, 2033 | Otsuka |
Abilify Mycite Kit | US10517507 | Communication system with enhanced partial power source and method of manufacturing same | Jun 13, 2032 | Otsuka |
Abilify Mycite Kit | US9320455 | Highly reliable ingestible event markers and methods for using the same | Dec 15, 2031 | Otsuka |
Abilify Mycite Kit | US11229378 | Communication system with enhanced partial power source and method of manufacturing same | Jul 11, 2031 | Otsuka |
Abilify Mycite Kit | US8547248 | Implantable zero-wire communications system | Dec 18, 2030 | Otsuka |
Abilify Mycite Kit | US8258962 | Multi-mode communication ingestible event markers and systems, and methods of using the same | Nov 25, 2030 | Otsuka |
Abilify Mycite Kit | US8961412 | In-body device with virtual dipole signal amplification | Nov 17, 2030 | Otsuka |
Abilify Mycite Kit | US9941931 | System for supply chain management | Nov 04, 2030 | Otsuka |
Abilify Mycite Kit | US11464423 | In-body power source having high surface area electrode | Sep 15, 2030 | Otsuka |
Abilify Mycite Kit | US8114021 | Body-associated receiver and method | Jun 21, 2030 | Otsuka |
Abilify Mycite Kit | US8545402 | Highly reliable ingestible event markers and methods for using the same | Apr 27, 2030 | Otsuka |
Abilify Mycite Kit | US8847766 | Pharma-informatics system | Mar 29, 2030 | Otsuka |
Abilify Mycite Kit | US9149577 | Body-associated receiver and method | Dec 15, 2029 | Otsuka |
Abilify Mycite Kit | US8718193 | Active signal processing personal health signal receivers | Dec 05, 2029 | Otsuka |
Abilify Mycite Kit | US9433371 | In-body device with virtual dipole signal amplification | Sep 15, 2029 | Otsuka |
Abilify Mycite Kit | US8945005 | Controlled activation ingestible identifier | Aug 19, 2029 | Otsuka |
Abilify Mycite Kit | US10441194 | Ingestible event marker systems | Jul 26, 2029 | Otsuka |
Abilify Mycite Kit | US8956288 | In-body power source having high surface area electrode | Jul 06, 2029 | Otsuka |
Abilify Mycite Kit | US8674825 | Pharma-informatics system | Apr 09, 2029 | Otsuka |
Abilify Mycite Kit | US9060708 | Multi-mode communication ingestible event markers and systems, and methods of using the same | Mar 05, 2029 | Otsuka |
Abilify Mycite Kit | US9258035 | Multi-mode communication ingestible event markers and systems, and methods of using the same | Mar 05, 2029 | Otsuka |
Abilify Mycite Kit | US9119554 | Pharma-informatics system | Dec 16, 2028 | Otsuka |
Abilify Mycite Kit | US9444503 | Active signal processing personal health signal receivers | Nov 19, 2027 | Otsuka |
Abilify | US8759350 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | Mar 02, 2027 | Otsuka |
Abilify | US8759350 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | Mar 02, 2027 | Otsuka |
Abilify Mycite Kit | US8759350 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | Mar 02, 2027 | Otsuka |
Abilify Mycite Kit | US7978064 | Communication system with partial power source | Sep 14, 2026 | Otsuka |
Abilify | US9125939 | Carbostyril derivatives and mood stabilizers for treating mood disorders | Jul 28, 2026 | Otsuka |
Abilify Mycite Kit | US9125939 | Carbostyril derivatives and mood stabilizers for treating mood disorders | Jul 28, 2026 | Otsuka |
Abilify Mycite Kit | US11476952 | Pharma-informatics system | Apr 28, 2026 | Otsuka |
Abilify Asimtufii | US8399469 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof | Jun 29, 2025 | Otsuka |
Abilify Maintena Kit | US8399469 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof | Jun 29, 2025 | Otsuka Pharm Co Ltd |
Abilify Asimtufii | US8338427 | Methods for administering aripiprazole | Mar 15, 2025 | Otsuka |
Abilify Maintena Kit | US8338427 | Methods for administering aripiprazole | Mar 15, 2025 | Otsuka Pharm Co Ltd |
Abilify |
US7115587 (Pediatric) | Aripiprazole complex formulation and method | Jan 21, 2025 | Otsuka |
Abilify |
US7550445 (Pediatric) | Aripiprazole complex formulation and method | Jan 21, 2025 | Otsuka |
Abilify |
US8017615 (Pediatric) | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Dec 16, 2024
(Expired) | Otsuka |
Abilify Maintena Kit | US7807680 | Controlled release sterile injectable aripiprazole formulation and method |
Oct 19, 2024
(Expired) | Otsuka Pharm Co Ltd |
Abilify Maintena Kit | US8030313 | Controlled release sterile injectable aripiprazole formulation and method |
Oct 19, 2024
(Expired) | Otsuka Pharm Co Ltd |
Abilify Maintena Kit | US8722679 | Controlled release sterile injectable aripiprazole formulation and method |
Oct 19, 2024
(Expired) | Otsuka Pharm Co Ltd |
Abilify | US7115587 | Aripiprazole complex formulation and method |
Jul 21, 2024
(Expired) | Otsuka |
Abilify | US7550445 | Aripiprazole complex formulation and method |
Jul 21, 2024
(Expired) | Otsuka |
Abilify | US8017615 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun 16, 2024
(Expired) | Otsuka |
Abilify Mycite Kit | US8017615 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun 16, 2024
(Expired) | Otsuka |
Abilify | US9387182 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec 25, 2023
(Expired) | Otsuka |
Abilify | US9387182 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec 25, 2023
(Expired) | Otsuka |
Abilify Mycite Kit | US9387182 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec 25, 2023
(Expired) | Otsuka |
Abilify Asimtufii | US8338428 | Methods for administering aripiprazole |
Aug 06, 2023
(Expired) | Otsuka |
Abilify Asimtufii | US8759351 | Methods for administering aripiprazole |
Aug 06, 2023
(Expired) | Otsuka |
Abilify Maintena Kit | US8338428 | Methods for administering aripiprazole |
Aug 06, 2023
(Expired) | Otsuka Pharm Co Ltd |
Abilify Maintena Kit | US8759351 | Methods for administering aripiprazole |
Aug 06, 2023
(Expired) | Otsuka Pharm Co Ltd |
Abilify |
US8580796 (Pediatric) | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar 25, 2023
(Expired) | Otsuka |
Abilify |
US8642760 (Pediatric) | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar 25, 2023
(Expired) | Otsuka |
Abilify |
US6977257 (Pediatric) | Aripiprazole oral solution |
Oct 24, 2022
(Expired) | Otsuka |
Abilify | US8580796 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep 25, 2022
(Expired) | Otsuka |
Abilify | US8642760 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep 25, 2022
(Expired) | Otsuka |
Abilify | US9359302 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep 25, 2022
(Expired) | Otsuka |
Abilify Maintena Kit | US8993761 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep 25, 2022
(Expired) | Otsuka Pharm Co Ltd |
Abilify Mycite Kit | US8580796 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep 25, 2022
(Expired) | Otsuka |
Abilify Mycite Kit | US8642760 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep 25, 2022
(Expired) | Otsuka |
Abilify Mycite Kit | US9359302 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep 25, 2022
(Expired) | Otsuka |
Abilify |
US8642600 (Pediatric) | Method of treating autism |
Jul 28, 2022
(Expired) | Otsuka |
Abilify |
US8642600 (Pediatric) | Method of treating autism |
Jul 28, 2022
(Expired) | Otsuka |
Abilify | US6977257 | Aripiprazole oral solution |
Apr 24, 2022
(Expired) | Otsuka |
Abilify | US7053092 | 5-HT1a receptor subtype agonist |
Jan 28, 2022
(Expired) | Otsuka |
Abilify | US7053092 | 5-HT1a receptor subtype agonist |
Jan 28, 2022
(Expired) | Otsuka |
Abilify | US8642600 | Method of treating autism |
Jan 28, 2022
(Expired) | Otsuka |
Abilify | US8642600 | Method of treating autism |
Jan 28, 2022
(Expired) | Otsuka |
Abilify | US9089567 | Method of treating cognitive impairments and schizophrenias |
Jan 28, 2022
(Expired) | Otsuka |
Abilify Maintena Kit | US9089567 | Method of treating cognitive impairments and schizophrenias |
Jan 28, 2022
(Expired) | Otsuka Pharm Co Ltd |
Abilify Mycite Kit | US7053092 | 5-HT1a receptor subtype agonist |
Jan 28, 2022
(Expired) | Otsuka |
Abilify Mycite Kit | US9089567 | Method of treating cognitive impairments and schizophrenias |
Jan 28, 2022
(Expired) | Otsuka |
Abilify |
US8518421 (Pediatric) | Flashmelt oral dosage formulation |
Jul 24, 2021
(Expired) | Otsuka |
Abilify | US8518421 | Flashmelt oral dosage formulation |
Jan 24, 2021
(Expired) | Otsuka |
Abilify | US9358207 | Flashmelt oral dosage formulation |
Apr 12, 2020
(Expired) | Otsuka |
Abilify |
US5006528 (Pediatric) | Carbostyril derivatives |
Apr 20, 2015
(Expired) | Otsuka |
Abilify |
US5006528 (Pediatric) | Carbostyril derivatives |
Apr 20, 2015
(Expired) | Otsuka |
Abilify Maintena Kit | US5006528 | Carbostyril derivatives |
Apr 20, 2015
(Expired) | Otsuka Pharm Co Ltd |
Abilify Maintena Kit |
US5006528 (Pediatric) | Carbostyril derivatives |
Apr 20, 2015
(Expired) | Otsuka Pharm Co Ltd |
Abilify | US5006528 | Carbostyril derivatives |
Oct 20, 2014
(Expired) | Otsuka |
Abilify | US5006528 | Carbostyril derivatives |
Oct 20, 2014
(Expired) | Otsuka |
Abilify Maintena Kit | US5006528 | Carbostyril derivatives |
Oct 20, 2014
(Expired) | Otsuka Pharm Co Ltd |
Aripiprazole's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Aripiprazole:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry. Aripiprazole has 2 clinical trials that have been verified in 2024. Out of these 2, 1 trial is in PHASE4.
Aripiprazole Generic API Manufacturers
Several generic applications have been filed for Aripiprazole. The first generic version for Aripiprazole was by Teva Pharmaceuticals Usa and was approved on Apr 28, 2015. And the latest generic version is by Mylan Pharmaceuticals Inc and was approved on Dec 3, 2024.
Given below is the list of companies who have filed for Aripiprazole generic, along with the locations of their manufacturing plants worldwide.
1. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 6 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
2MG | tablet | Prescription | ORAL | AB | Dec 7, 2016 |
30MG | tablet | Prescription | ORAL | AB | Dec 7, 2016 |
20MG | tablet | Prescription | ORAL | AB | Dec 7, 2016 |
15MG | tablet | Prescription | ORAL | AB | Dec 7, 2016 |
10MG | tablet | Prescription | ORAL | AB | Dec 7, 2016 |
5MG | tablet | Prescription | ORAL | AB | Dec 7, 2016 |
2. AJANTA PHARMA LTD
Ajanta Pharma Ltd has filed for 6 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Ajanta Pharma Ltd.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
30MG | tablet | Prescription | ORAL | AB | Sep 12, 2016 |
20MG | tablet | Prescription | ORAL | AB | Sep 12, 2016 |
15MG | tablet | Prescription | ORAL | AB | Sep 12, 2016 |
10MG | tablet | Prescription | ORAL | AB | Sep 12, 2016 |
5MG | tablet | Prescription | ORAL | AB | Sep 12, 2016 |
2MG | tablet | Prescription | ORAL | AB | Sep 12, 2016 |
Manufacturing Plant Locations New
Ajanta Pharma Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Ajanta Pharma Ltd as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
India |
|
3. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 6 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Alembic.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
2MG | tablet | Prescription | ORAL | AB | Apr 28, 2015 |
5MG | tablet | Prescription | ORAL | AB | Apr 28, 2015 |
10MG
(reference standard) | tablet, orally disintegrating | Prescription | ORAL | AB | Apr 28, 2015 |
15MG | tablet, orally disintegrating | Prescription | ORAL | AB | Apr 28, 2015 |
20MG | tablet | Prescription | ORAL | AB | Apr 28, 2015 |
30MG | tablet | Prescription | ORAL | AB | Apr 28, 2015 |
Manufacturing Plant Locations New
Alembic's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Alembic as present at those locations.
Country | City | Firm Name | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
India |
|
4. ALKEM LABS LTD
Alkem Laboratories Ltd has filed for 6 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
2MG | tablet | Prescription | ORAL | AB | Feb 21, 2019 |
30MG | tablet | Prescription | ORAL | AB | Feb 21, 2019 |
15MG | tablet | Prescription | ORAL | AB | Feb 21, 2019 |
20MG | tablet | Prescription | ORAL | AB | Feb 21, 2019 |
5MG | tablet | Prescription | ORAL | AB | Feb 21, 2019 |
10MG | tablet | Prescription | ORAL | AB | Feb 21, 2019 |
5. AMNEAL PHARMS
Amneal Pharmaceuticals has filed for 7 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Amneal Pharms.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
1MG/ML
(reference standard) | solution | Prescription | ORAL | AA | Aug 14, 2015 |
2MG | tablet | Prescription | ORAL | AB | Jun 17, 2016 |
30MG | tablet | Prescription | ORAL | AB | Jun 17, 2016 |
20MG | tablet | Prescription | ORAL | AB | Jun 17, 2016 |
15MG | tablet | Prescription | ORAL | AB | Jun 17, 2016 |
10MG | tablet | Prescription | ORAL | AB | Jun 17, 2016 |
5MG | tablet | Prescription | ORAL | AB | Jun 17, 2016 |
6. APOTEX
Apotex Inc has filed for 7 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Apotex.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
20MG | tablet | Prescription | ORAL | AB | Jul 24, 2015 |
15MG | tablet | Prescription | ORAL | AB | Jul 24, 2015 |
10MG | tablet | Prescription | ORAL | AB | Jul 24, 2015 |
5MG | tablet | Prescription | ORAL | AB | Jul 24, 2015 |
2MG | tablet | Prescription | ORAL | AB | Jul 24, 2015 |
30MG | tablet | Prescription | ORAL | AB | Jul 24, 2015 |
1MG/ML | solution | Prescription | ORAL | AA | Sep 30, 2015 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
Country | City | Firm Name | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States |
| |||||||||||||
Canada |
| |||||||||||||
India |
|
7. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 6 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
2MG | tablet | Prescription | ORAL | AB | Oct 8, 2015 |
10MG | tablet | Prescription | ORAL | AB | Oct 8, 2015 |
30MG | tablet | Prescription | ORAL | AB | Oct 8, 2015 |
20MG | tablet | Prescription | ORAL | AB | Oct 8, 2015 |
15MG | tablet | Prescription | ORAL | AB | Oct 8, 2015 |
5MG | tablet | Prescription | ORAL | AB | Oct 8, 2015 |
Manufacturing Plant Locations New
Aurobindo Pharma's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma as present at those locations.
Country | City | Firm Name | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
India |
| |||||||||
United States |
|
8. AUROBINDO PHARMA LTD
Aurobindo Pharma Ltd has filed for 1 generic for Aripiprazole. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
1MG/ML | solution | Prescription | ORAL | AA | Jan 29, 2019 |
Manufacturing Plant Locations New
Aurobindo Pharma Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma Ltd as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
India |
|
9. BRECKENRIDGE
Breckenridge Pharmaceutical Inc has filed for 6 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Breckenridge.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
2MG | tablet | Discontinued | ORAL | N/A | Jan 9, 2017 |
5MG | tablet | Discontinued | ORAL | N/A | Jan 9, 2017 |
30MG | tablet | Discontinued | ORAL | N/A | Jan 9, 2017 |
20MG | tablet | Discontinued | ORAL | N/A | Jan 9, 2017 |
15MG | tablet | Discontinued | ORAL | N/A | Jan 9, 2017 |
10MG | tablet | Discontinued | ORAL | N/A | Jan 9, 2017 |
Manufacturing Plant Locations New
Breckenridge's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Breckenridge as present at those locations.
Country | City | Firm Name | ||||
---|---|---|---|---|---|---|
United States |
|
10. CHARTWELL RX
Chartwell Rx Sciences Llc has filed for 1 generic for Aripiprazole. Given below are the details of the strengths of this generic introduced by Chartwell Rx.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
1MG/ML | solution | Prescription | ORAL | AA | Oct 25, 2022 |
11. HETERO LABS LTD III
Hetero Labs Ltd Unit Iii has filed for 1 generic for Aripiprazole. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Iii.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
1MG/ML | solution | Prescription | ORAL | AA | Nov 1, 2023 |
12. HETERO LABS LTD V
Hetero Labs Ltd Unit V has filed for 6 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd V.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
30MG | tablet | Prescription | ORAL | AB | Apr 28, 2015 |
20MG | tablet | Prescription | ORAL | AB | Apr 28, 2015 |
15MG | tablet | Prescription | ORAL | AB | Apr 28, 2015 |
10MG | tablet | Prescription | ORAL | AB | Apr 28, 2015 |
5MG | tablet | Prescription | ORAL | AB | Apr 28, 2015 |
2MG | tablet | Prescription | ORAL | AB | Apr 28, 2015 |
13. LANNETT CO INC
Lannett Co Inc has filed for 1 generic for Aripiprazole. Given below are the details of the strengths of this generic introduced by Lannett Co Inc.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
1MG/ML | solution | Prescription | ORAL | AA | Aug 14, 2015 |
14. LUPIN
Lupin Inc has filed for 6 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Lupin.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
30MG | tablet | Prescription | ORAL | AB | Mar 18, 2024 |
2MG | tablet | Prescription | ORAL | AB | Mar 18, 2024 |
5MG | tablet | Prescription | ORAL | AB | Mar 18, 2024 |
10MG | tablet | Prescription | ORAL | AB | Mar 18, 2024 |
15MG | tablet | Prescription | ORAL | AB | Mar 18, 2024 |
20MG | tablet | Prescription | ORAL | AB | Mar 18, 2024 |
Manufacturing Plant Locations New
Lupin's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Lupin as present at those locations.
Country | City | Firm Name | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
India |
| |||||||||||||||||||||||||||||
United States |
|
15. MACLEODS PHARMS LTD
Macleods Pharmaceuticals Ltd has filed for 6 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Macleods Pharms Ltd.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
10MG | tablet | Prescription | ORAL | AB | Oct 7, 2016 |
2MG | tablet | Prescription | ORAL | AB | Oct 7, 2016 |
5MG | tablet | Prescription | ORAL | AB | Oct 7, 2016 |
15MG | tablet | Prescription | ORAL | AB | Oct 7, 2016 |
20MG | tablet | Prescription | ORAL | AB | Oct 7, 2016 |
30MG | tablet | Prescription | ORAL | AB | Oct 7, 2016 |
16. MYLAN
Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Mylan.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
300MG/VIAL | for suspension, extended release | Prescription | INTRAMUSCULAR | AP | Dec 3, 2024 |
400MG/VIAL | for suspension, extended release | Prescription | INTRAMUSCULAR | AP | Dec 3, 2024 |
Manufacturing Plant Locations New
Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.
Country | City | Firm Name | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States |
| |||||||||||||||||
India |
| |||||||||||||||||
Canada |
| |||||||||||||||||
Ireland |
|
17. NORVIUM BIOSCIENCE
Norvium Bioscience Llc has filed for 6 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Norvium Bioscience.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
30MG | tablet | Discontinued | ORAL | N/A | Sep 19, 2018 |
5MG | tablet | Discontinued | ORAL | N/A | Sep 19, 2018 |
2MG | tablet | Discontinued | ORAL | N/A | Sep 19, 2018 |
10MG | tablet | Discontinued | ORAL | N/A | Sep 19, 2018 |
20MG | tablet | Discontinued | ORAL | N/A | Sep 19, 2018 |
15MG | tablet | Discontinued | ORAL | N/A | Sep 19, 2018 |
18. ORBION PHARMS
Orbion Pharmaceuticals Private Ltd has filed for 6 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Orbion Pharms.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
30MG | tablet | Prescription | ORAL | AB | May 23, 2017 |
20MG | tablet | Prescription | ORAL | AB | May 23, 2017 |
15MG | tablet, orally disintegrating | Prescription | ORAL | AB | Dec 11, 2017 |
10MG | tablet, orally disintegrating | Prescription | ORAL | AB | Dec 11, 2017 |
5MG | tablet | Prescription | ORAL | AB | May 23, 2017 |
2MG | tablet | Prescription | ORAL | AB | May 23, 2017 |
19. PRINSTON INC
Prinston Pharmaceutical Inc has filed for 6 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Prinston Inc.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
30MG | tablet | Prescription | ORAL | AB | Dec 4, 2017 |
5MG | tablet | Prescription | ORAL | AB | Dec 4, 2017 |
10MG | tablet | Prescription | ORAL | AB | Dec 4, 2017 |
15MG | tablet | Prescription | ORAL | AB | Dec 4, 2017 |
20MG | tablet | Prescription | ORAL | AB | Dec 4, 2017 |
2MG | tablet | Prescription | ORAL | AB | Dec 4, 2017 |
20. RUBICON
Rubicon Research Private Ltd has filed for 1 generic for Aripiprazole. Given below are the details of the strengths of this generic introduced by Rubicon.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
1MG/ML | solution | Prescription | ORAL | AA | Oct 27, 2022 |
Manufacturing Plant Locations New
Rubicon's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Rubicon as present at those locations.
Country | City | Firm Name | ||||
---|---|---|---|---|---|---|
United States |
| |||||
Canada |
| |||||
India |
|
21. SCIEGEN PHARMS INC
Sciegen Pharmaceuticals Inc has filed for 6 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Sciegen Pharms Inc.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
30MG | tablet | Prescription | ORAL | AB | Sep 29, 2016 |
20MG | tablet | Prescription | ORAL | AB | Sep 29, 2016 |
15MG | tablet, orally disintegrating | Prescription | ORAL | AB | Apr 18, 2018 |
10MG | tablet, orally disintegrating | Prescription | ORAL | AB | Apr 18, 2018 |
5MG | tablet | Prescription | ORAL | AB | Sep 29, 2016 |
2MG | tablet | Prescription | ORAL | AB | Sep 29, 2016 |
22. SQUARE PHARMS
Square Pharmaceuticals Ltd has filed for 4 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Square Pharms.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
20MG | tablet, orally disintegrating | Prescription | ORAL | N/A | Aug 28, 2018 |
30MG | tablet, orally disintegrating | Prescription | ORAL | N/A | Aug 28, 2018 |
15MG | tablet, orally disintegrating | Prescription | ORAL | AB | Aug 28, 2018 |
10MG | tablet, orally disintegrating | Prescription | ORAL | AB | Aug 28, 2018 |
23. SUNSHINE
Sunshine Lake Pharma Co Ltd has filed for 3 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Sunshine.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
10MG | tablet | Prescription | ORAL | AB | Oct 2, 2023 |
2MG | tablet | Prescription | ORAL | AB | Oct 2, 2023 |
5MG | tablet | Prescription | ORAL | AB | Oct 2, 2023 |
Manufacturing Plant Locations New
Sunshine's manufacturing plants are situated in 6 countries - United States, Peru, India, Thailand, China, Mozambique. Given below are the details of these plant locations as well as the firm names of Sunshine as present at those locations.
Country | City | Firm Name | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States |
| |||||||||||||||||||||||||||||||||||||||||
Peru |
| |||||||||||||||||||||||||||||||||||||||||
India |
| |||||||||||||||||||||||||||||||||||||||||
Thailand |
| |||||||||||||||||||||||||||||||||||||||||
China |
| |||||||||||||||||||||||||||||||||||||||||
Mozambique |
|
24. TEVA PHARMS USA
Teva Pharmaceuticals Usa has filed for 6 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
2MG | tablet | Discontinued | ORAL | N/A | Apr 28, 2015 |
5MG | tablet | Discontinued | ORAL | N/A | Apr 28, 2015 |
10MG | tablet | Discontinued | ORAL | N/A | Apr 28, 2015 |
15MG | tablet | Discontinued | ORAL | N/A | Apr 28, 2015 |
20MG | tablet | Discontinued | ORAL | N/A | Apr 28, 2015 |
30MG | tablet | Discontinued | ORAL | N/A | Apr 28, 2015 |
25. TORRENT
Torrent Pharmaceuticals Ltd has filed for 6 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Torrent.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
2MG | tablet | Prescription | ORAL | AB | Apr 28, 2015 |
5MG | tablet | Prescription | ORAL | AB | Apr 28, 2015 |
10MG | tablet | Prescription | ORAL | AB | Apr 28, 2015 |
15MG | tablet | Prescription | ORAL | AB | Apr 28, 2015 |
20MG | tablet | Prescription | ORAL | AB | Apr 28, 2015 |
30MG | tablet | Prescription | ORAL | AB | Apr 28, 2015 |
Manufacturing Plant Locations New
Torrent's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Torrent as present at those locations.
Country | City | Firm Name | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
India |
| |||||||||||
United States |
|
26. UNICHEM
Unichem Laboratories Ltd has filed for 6 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Unichem.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
5MG | tablet | Prescription | ORAL | AB | Dec 1, 2021 |
10MG | tablet | Prescription | ORAL | AB | Dec 1, 2021 |
30MG | tablet | Prescription | ORAL | AB | Dec 1, 2021 |
15MG | tablet | Prescription | ORAL | AB | Dec 1, 2021 |
20MG | tablet | Prescription | ORAL | AB | Dec 1, 2021 |
2MG | tablet | Prescription | ORAL | AB | Dec 1, 2021 |
Manufacturing Plant Locations New
Unichem's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Unichem as present at those locations.
Country | City | Firm Name | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
India |
| |||||||||||||
United States |
|
27. VISTAPHARM
Vistapharm Inc has filed for 1 generic for Aripiprazole. Given below are the details of the strengths of this generic introduced by Vistapharm.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
1MG/ML | solution | Prescription | ORAL | AA | Dec 26, 2019 |
28. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 6 different strengths of generic version for Aripiprazole. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
2MG | tablet | Discontinued | ORAL | N/A | Jan 7, 2019 |
15MG | tablet | Discontinued | ORAL | N/A | Jan 7, 2019 |
20MG | tablet | Discontinued | ORAL | N/A | Jan 7, 2019 |
30MG | tablet | Discontinued | ORAL | N/A | Jan 7, 2019 |
10MG | tablet | Discontinued | ORAL | N/A | Jan 7, 2019 |
5MG | tablet | Discontinued | ORAL | N/A | Jan 7, 2019 |